EZH2 and esophageal squamous cell carcinoma: In summary, CRISPR–Cas9‐mediated genome‐wide GOF screening identified that EZH2 rendered ESCC cells resistant to the PI3Kα inhibitor CYH33, which was associated with EZH2‐mediated cell cycle progression via the p21‐RB axis.